Bortezomib is a Intravenous Injection in the Human Prescription Drug category. It is labeled and distributed by Fosun Pharma Usa Inc. The primary component is Bortezomib.
Product ID | 72266-243_e6718dc6-ebc8-570b-e053-2a95a90a86ba |
NDC | 72266-243 |
Product Type | Human Prescription Drug |
Proprietary Name | Bortezomib |
Generic Name | Bortezomib |
Dosage Form | Injection |
Route of Administration | INTRAVENOUS |
Marketing Start Date | 2022-08-23 |
Marketing Category | NDA / |
Application Number | NDA215331 |
Labeler Name | FOSUN PHARMA USA INC |
Substance Name | BORTEZOMIB |
Active Ingredient Strength | 1 mg/1 |
Pharm Classes | Proteasome Inhibitor [EPC], Proteasome Inhibitors [MoA] |
NDC Exclude Flag | N |
Listing Certified Through | 2023-12-31 |
Marketing Start Date | 2022-08-23 |
NDC Exclude Flag | N |
Sample Package? | N |
NDC | Brand Name | Generic Name |
---|---|---|
0143-9098 | bortezomib | bortezomib |
0409-1700 | Bortezomib | Bortezomib |
0409-1703 | BORTEZOMIB | BORTEZOMIB |
0409-1704 | BORTEZOMIB | BORTEZOMIB |
0781-3258 | bortezomib | bortezomib for injection |
10019-991 | BORTEZOMIB | bortezomib |
25021-244 | BORTEZOMIB | BORTEZOMIB |
43598-426 | Bortezomib | Bortexomib |
43598-865 | Bortezomib | Bortexomib |
50742-484 | Bortezomib | Bortezomib |
51817-586 | Bortezomib | bortezomib |
55150-337 | BORTEZOMIB | BORTEZOMIB |
60505-6050 | BORTEZOMIB | bortezomib |
63323-721 | Bortezomib | Bortezomib |
63323-821 | Bortezomib | Bortezomib |
67184-0530 | Bortezomib | Bortezomib |
68001-534 | Bortezomib | Bortezomib |
68001-540 | Bortezomib | Bortezomib |
68001-541 | Bortezomib | Bortezomib |
70511-161 | Bortezomib | bortezomib |
70511-162 | Bortezomib | bortezomib |
70710-1411 | BORTEZOMIB | BORTEZOMIB |
70771-1708 | BORTEZOMIB | BORTEZOMIB |
70860-225 | Bortezomib | bortezomib |
71288-118 | Bortezomib | Bortezomib |
72205-183 | Bortezomib | Bortezomib |
72266-243 | Bortezomib | bortezomib |
72266-244 | Bortezomib | bortezomib |
63020-049 | VELCADE | bortezomib |